ClinicalTrials.gg
CompletedNCT06453642GPXUpdated Nov 19, 2026Results posted

Evaluation of a Simple-Prep Controlled Embolic

An interventional study of GPX® Embolic Device in Embolization, Hypervascular Tumor and Renal Angiomyolipoma, sponsored by Fluidx Medical Technology, Inc.. Completed at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Fluidx Medical Technology, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 155 open to participants now, 278 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
242nd of 1,010
114 · median 40
Started
2024
with 37 others
No phase
98 of 1,144
15 open now
Registered
1,050th of 1,144
by date

Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 242nd largest by enrollment of the 1,010 interventional ones that give a count, is one of 38 that started in 2024, is one of 98 with no phase, and was the 1,050th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

155 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

150 more — sign in →

All 155 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,144 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.

Read the detailed description

The investigation is a single-arm, open-label, non-randomized, prospective, multicenter, multinational pivotal study. Subjects will undergo distal embolization in the peripheral vasculature, including vascular tumors, renal embolizations, and portal vein branches, with the GPX® Embolic Device and will then be followed 30-days post-procedure.

03

Conditions studied

  • Embolization
  • Hypervascular Tumor
  • Renal Angiomyolipoma
  • Renal Cell Carcinoma
  • Bone Tumor
  • Portal Vein Embolization

Keywords

  • Embolization
  • Distal Embolization
  • Distal Vessel Penetration
  • Peripheral Vasculature
  • GPX Embolic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years on the date of consent
  2. Expected post-procedural lifespan of at least 30 days, in the opinion of the investigator, to allow for participation in all follow-up visits
  3. Presents with need for peripheral embolization where there is a desire for distal vessel bed penetration including:

    • Vascular tumors (e.g., renal angiomyolipoma, renal cell carcinoma, bone tumors, bleeding tumors, and other vascular tumors)
    • Renal embolization
    • Portal vein branches
  4. granted by the patient or legally authorized representative
  5. Willing and able to comply with the protocol-specified procedures and assessments

Exclusion criteria

Exclusion Criteria:

  1. Requires embolization for any of the following applications: a) Neurovasculature b) Coronary vasculature c) Hemorrhage due to trauma d) Non-tumoral focal/active bleeding sites (e.g., gastrointestinal tract, urinary tract, lung) e) Veins other than portal vein f) Aneurysms g) Endoleaks h) Vascular malformations i) Vessels for flow redistribution
  2. Has undergone an embolization procedure within 30 days prior to consent
  3. Presents with need for embolization where the risk of infarction outweighs the benefit of distal penetration (e.g., gastrointestinal, uterine)
  4. Embolization target is only intended for temporary occlusion (e.g., bioresorbable biologic embolic agents)
  5. Known allergy or to contrast media that cannot be adequately medicated
  6. Pregnant, planning to become pregnant during the study period, or breastfeeding
  7. Unresolved systemic infection or localized infection in the targeted region
  8. Pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the investigator, would clinically confound the study primary endpoints
  9. Existing medical condition which, in the opinion of the investigator, may cause the subject to be intolerant of an occlusion procedure or non-compliant with the protocol or may confound the data interpretation
  10. Subject is participating in another device, drug, or procedure clinical investigation and has not completed the study treatment or the other investigation clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)
  11. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults) 12. Patients with drug or alcohol dependency (within 6 months prior to study entry) that, in the opinion of the investigator, would interfere with safe delivery of the study treatment or with the interpretation of study results

Intra-procedural exclusion criteria:

13. Presence of persistent, flow-limiting vasospasm that is not responsive to chemical or mechanical interventions 14. Presence of collateral pathways potentially endangering normal territories during embolization 15. Blood flow precludes safe delivery of embolic material (e.g., arteriovenous shunting or high, unpredictable flow exists) 16. Anatomy that precludes advancement of the delivery device to target vessel embolization site or delivery of embolic material 17. Dissection in the target vessel 18. The delivery device has already been used with an ionic contrast agent (e.g., Conray® (iothalamate meglumine injection USP 60%), Guerbet)

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    GPX® Embolic Device

    Device: GPX® Embolic Device

Interventions

  • DeviceGPX® Embolic Device

    Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches

06

What researchers measure

Primary outcomes

  1. Number of Participants With Freedom From Major Adverse Events (MAEs)

    MAEs are defined as: * Nontarget embolization with ischemia in an unintended anatomical area * Systemic allergic and/or toxic reaction to the GPX Embolic Device * Catheter entrapment and/or breakage * Culture-proven abscess in target organ/tissue * Embolization-related death

    Time frame: Index procedure through 30-day follow-up

  2. Number of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s)

    Determined by the investigator during procedure

    Time frame: During procedure (an average of 1 to 3 hours) after device (GPX) delivery

  3. Number of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s)

    Determined by the core lab via comparison of the pre- and final post-embolization images

    Time frame: End of procedure, an average of 1 to 3 hours

Secondary outcomes

  1. Number of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure

    Time frame: 30-day follow-up

  2. Number of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure

    Time frame: End of procedure, an average of 1 to 3 hours

  3. Number of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material

    Time frame: End of procedure, an average of 1 to 3 hours

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneGPX® Embolic Device
Started114
Completed113
Not completed1

Outcome measures

PrimaryNumber of Participants With Freedom From Major Adverse Events (MAEs)

MAEs are defined as: * Nontarget embolization with ischemia in an unintended anatomical area * Systemic allergic and/or toxic reaction to the GPX Embolic Device * Catheter entrapment and/or breakage * Culture-proven abscess in target organ/tissue * Embolization-related death

Time frame:
Index procedure through 30-day follow-up
Reported as:
Count of participants · Participants
Number of Participants With Freedom From Major Adverse Events (MAEs)
ParticipantsGPX® Embolic Device
Number of Participants With Freedom From Major Adverse Events (MAEs)113
PrimaryNumber of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s)

Determined by the investigator during procedure

Time frame:
During procedure (an average of 1 to 3 hours) after device (GPX) delivery
Reported as:
Count of participants · Participants
Number of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s)
ParticipantsGPX® Embolic Device
Number of Participants With Successful Delivery of the GPX Embolic Device to the Target Vessel Embolization Site(s)114
PrimaryNumber of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s)

Determined by the core lab via comparison of the pre- and final post-embolization images

Time frame:
End of procedure, an average of 1 to 3 hours
Reported as:
Count of participants · Participants
Number of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s)
ParticipantsGPX® Embolic Device
Number of Participants With Successful Occlusion of Flow Immediately Beyond the Target Vessel Embolization Site(s)109
SecondaryNumber of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure
Time frame:
30-day follow-up
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure
ParticipantsGPX® Embolic Device
Number of Participants With Occurrence of Device-related Adverse Events (AE) Through 30 Days Post-index Procedure6
SecondaryNumber of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure
Time frame:
End of procedure, an average of 1 to 3 hours
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure
ParticipantsGPX® Embolic Device
Number of Participants With Occurrence of Adjunctive Embolization Agent Usage During the Embolization Procedure1
SecondaryNumber of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material
Time frame:
End of procedure, an average of 1 to 3 hours
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material
ParticipantsGPX® Embolic Device
Number of Participants With Occurrence of Catheter Occlusion Due to the GPX Embolic Material0

Adverse events

Collected over All adverse events (AEs) were collected from the start of the embolization procedure for all enrolled subjects and assessed throughout the study (30-day follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GPX® Embolic Device0/114 (0%)30/114 (26.3%)19/114 (16.7%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventGPX® Embolic Device
Post embolisation syndromeInjury, poisoning and procedural complications12/114
HyponatraemiaMetabolism and nutrition disorders2/114
Skin necrosisSkin and subcutaneous tissue disorders2/114
CholangitisHepatobiliary disorders2/114
Abdominal pain upperGastrointestinal disorders1/114
AbscessInfections and infestations1/114
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/114
AnaemiaBlood and lymphatic system disorders1/114
CholecystitisHepatobiliary disorders1/114
Flank painMusculoskeletal and connective tissue disorders1/114
Most frequent other events
Most frequent other events
EventGPX® Embolic Device
Post embolisation syndromeInjury, poisoning and procedural complications19/114

Baseline characteristics

Age, Continuous
Age, Continuous(years)GPX® Embolic Device
Mean61.1 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)GPX® Embolic Device
Female56
Male58
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GPX® Embolic Device
Hispanic or Latino15
Not Hispanic or Latino98
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GPX® Embolic Device
American Indian or Alaska Native1
Asian6
Black or African American11
Native Hawaiian or other Pacific Islander1
White81
Other14
Subject chose not to disclose1
Region of Enrollment
Region of Enrollment(participants)GPX® Embolic Device
New Zealand12
Canada15
United States87
08

Study locations

20 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jan 2026, 14 months.

Results were first posted in Nov 2026, 9 months after primary completion.

Of 127 interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 114. This study's 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2026 → Jan 2026 and completion Sep 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 11, 2024
StartActual
Nov 18, 2024
Primary completionActual
Jan 26, 2026was May 2026
CompletionActual
Jan 26, 2026was Sep 2026
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Results
Results posted
posted Nov 19, 2026
Primary completion
May 2026→Jan 26, 2026 (actual)
Nov 19, 2026
Study completion
Sep 2026→Jan 26, 2026 (actual)
Nov 19, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedNumber of Participants With Freedom from major adverse eventsFrom Major Adverse Events (MAEs)Time frame: Index procedure through 30-day follow-up
  • EditedSingle binomial proportionNumber of successful deliveryParticipants With Successful Delivery of the GPX Embolic Device to the target vessel embolization siteTarget Vessel Embolization Site(s)Time frame: During procedure → During procedure (an average of 1 to 3 hours) after device (GPX) delivery
  • EditedSingle binomial proportionNumber of successful occlusionParticipants With Successful Occlusion of flow immediately beyondFlow Immediately Beyond the target vessel embolization siteTarget Vessel Embolization Site(s)Time frame: End of procedure → End of procedure, an average of 1 to 3 hours
Nov 19, 2026
Documents
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedNumber of Participants With Occurrence of deviceDevice-related adverse eventsAdverse Events (AE) throughThrough 30 days postDays Post-index procedureProcedureTime frame: 30-day follow-up
  • EditedNumber of Participants With Occurrence of adjunctive embolization agent usage duringAdjunctive Embolization Agent Usage During the embolization procedureEmbolization ProcedureTime frame: End of procedure → End of procedure, an average of 1 to 3 hours
  • EditedNumber of Participants With Occurrence of catheter occlusion dueCatheter Occlusion Due to the GPX Embolic MaterialTime frame: End of procedure → End of procedure, an average of 1 to 3 hours
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion May 2026→Jan 26, 2026 (now actual)
    Study completion Sep 2026→Jan 26, 2026 (now actual)
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedNumber of Participants With Freedom from major adverse eventsFrom Major Adverse Events (MAEs)Time frame: Index procedure through 30-day follow-up
    • EditedSingle binomial proportionNumber of successful deliveryParticipants With Successful Delivery of the GPX Embolic Device to the target vessel embolization siteTarget Vessel Embolization Site(s)Time frame: During procedure → During procedure (an average of 1 to 3 hours) after device (GPX) delivery
    • EditedSingle binomial proportionNumber of successful occlusionParticipants With Successful Occlusion of flow immediately beyondFlow Immediately Beyond the target vessel embolization siteTarget Vessel Embolization Site(s)Time frame: End of procedure → End of procedure, an average of 1 to 3 hours
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedNumber of Participants With Occurrence of deviceDevice-related adverse eventsAdverse Events (AE) throughThrough 30 days postDays Post-index procedureProcedureTime frame: 30-day follow-up
    • EditedNumber of Participants With Occurrence of adjunctive embolization agent usage duringAdjunctive Embolization Agent Usage During the embolization procedureEmbolization ProcedureTime frame: End of procedure → End of procedure, an average of 1 to 3 hours
    • EditedNumber of Participants With Occurrence of catheter occlusion dueCatheter Occlusion Due to the GPX Embolic MaterialTime frame: End of procedure → End of procedure, an average of 1 to 3 hours
    + 4 other changes: verification date, conditions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06453642
Lead sponsor
Fluidx Medical Technology, Inc.
Collaborators
Bright Research Partners
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Nov 18, 2024
Primary completion
Jan 26, 2026
Completion
Jan 26, 2026
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Michael Darcy, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion